Where is the radiobiology and pharmacology research to improve outcomes in glioblastoma?

Personalized medicine has been helpful for drug development in diseases with single and relatively stable gene mutations. The benefit for complex solid tumours with heterogeneous and changing genetic profiles is less clear. Whether it is efficient to continue diverting resources from combined biological and pharmacological approaches to trial new and existing genetic ‘targeted therapies’ for brain tumours is unknown but of developing concern in resource constrained environments.

[1]  B. O'neill,et al.  Glioblastoma survival in the United States before and during the temozolomide era , 2012, Journal of Neuro-Oncology.

[2]  A. Omuro,et al.  Current Role of Anti-Angiogenic Strategies for Glioblastoma , 2014, Current Treatment Options in Oncology.

[3]  P. Sminia,et al.  The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells , 2015, Journal of Neuro-Oncology.

[4]  S. Rose,et al.  New imaging techniques for more effective treatment in glioblastoma , 2014, Internal medicine journal.

[5]  P. Sminia,et al.  Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation , 2012, Journal of Neuro-Oncology.

[6]  M. Weller.  Are we ready for a randomized trial of valproic acid in newly diagnosed glioblastoma? , 2013, Neuro-oncology.

[7]  Jihyun Kim,et al.  Inhibition of mutated BRAF in melanoma. , 2010, The New England journal of medicine.

[8]  J. Fontenele,et al.  Potential Role for Valproate in the Treatment of High-Risk Brain Tumors of Childhood—Results from a Retrospective Observational Cohort Study , 2011, Pediatric hematology and oncology.

[9]  Bin Chen,et al.  Novel HDAC Inhibitors with Radiosensitizing Properties , 2005, Radiation research.

[10]  J. Apperley,et al.  Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia , 2009, Clinical Cancer Research.

[11]  Caterina Giannini,et al.  Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  I. Germano,et al.  Molecular response of human glioblastoma multiforme cells to ionizing radiation: cell cycle arrest, modulation of the expression of cyclin-dependent kinase inhibitors, and autophagy. , 2003, Journal of neurosurgery.

[13]  R. Addeo,et al.  ASCO 2013: bevacizumab and glioblastoma – a marriage dissolution? , 2014, Current medical research and opinion.

[14]  Deric M. Park,et al.  The Evidence of Glioblastoma Heterogeneity , 2015, Scientific Reports.

[15]  Ping Zhu,et al.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells , 2001, The EMBO journal.